HKU Scholars Hub: Browsing DSpace

Browsing by Author Bray, Mark R.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 14 of 14

	Title	Author(s)	Issue Date
	2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation Journal:Proceedings of the National Academy of Sciences of the United States of America	Duncan, Gordon S.Brenner, Dirk Tusche, Michael W.Brus̈tle, Anne Knobbe, Christiane B.Elia, Andrew J.Mock, Thomas Bray, Mark R.Krammer, Peter H.Mak, Tak W.	2012
	Author Correction: Fcmr regulates mononuclear phagocyte control of anti-tumor immunity (Nature Communications, (2019), 10, 1, (2678), 10.1038/s41467-019-10619-w) Journal:Nature Communications	Kubli, Shawn P.Vornholz, Larsen Duncan, Gordon Zhou, Wenjing Ramachandran, Parameswaran Fortin, Jerome Cox, Maureen Han, Seong Jun Nechanitzky, Robert Nechanitzky, Duygu Snow, Bryan E.Jones, Lisa Li, Wanda Y.Haight, Jillian Wakeham, Andrew Bray, Mark R.Mak, Tak W.	2019
	Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK Journal:Bioorganic and Medicinal Chemistry Letters	Laufer, Radoslaw Li, Sze Wan Liu, Yong Ng, Grace Lang, Yunhui Feher, Miklos Brokx, Richard Beletskaya, Irina Hodgson, Richard Mao, Guodong Plotnikova, Olga Awrey, Donald E.Mason, Jacqueline M.Wei, Xin Lin, Dan Chi Chia Che, Yi Kiarash, Reza Madeira, Brian Fletcher, Graham C.Mak, Tak W.Bray, Mark R.Pauls, Henry W.	2016
	Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent Journal:ACS Medicinal Chemistry Letters	Liu, Yong Laufer, Radoslaw Patel, Narendra Kumar Ng, Grace Sampson, Peter B.Li, Sze Wan Lang, Yunhui Feher, Miklos Brokx, Richard Beletskaya, Irina Hodgson, Richard Plotnikova, Olga Awrey, Donald E.Qiu, Wei Chirgadze, Nickolay Y.Mason, Jacqueline M.Wei, Xin Lin, Dan Chi Chia Che, Yi Kiarash, Reza Fletcher, Graham C.Mak, Tak W.Bray, Mark R.Pauls, Henry W.	2016
	DJ-1, a novel regulator of the tumor suppressor PTEN Journal:Cancer Cell	Kim, Raymond H.Peters, Malte Jang, Yingju Shi, Wei Pintilie, Melania Fletcher, Graham C.DeLuca, Carmela Liepa, Jennifer Zhou, Lily Snow, Bryan Binari, Richard C.Manoukian, Armen S.Bray, Mark R.Liu, Fei Fei Tsao, Ming Sound Mak, Tak W.	2005
	Fcmr regulates mononuclear phagocyte control of anti-tumor immunity Journal:Nature Communications	Kubli, Shawn P.Vornholz, Larsen Duncan, Gordon Zhou, Wenjing Ramachandran, Parameswaran Fortin, Jerome Cox, Maureen Han, Seong Jun Nechanitzky, Robert Nechanitzky, Duygu Snow, Bryan E.Jones, Lisa Li, Wanda Y.Haight, Jillian Wakeham, Andrew Bray, Mark R.Mak, Tak W.	2019
	Functional characterization of CFI-400945, a polo-like kinase 4 inhibitor, as a potential anticancer agent Journal:Cancer Cell	Mason, Jacqueline M.Lin, Dan Chi Chia Wei, Xin Che, Yi Yao, Yi Kiarash, Reza Cescon, David W.Fletcher, Graham C.Awrey, Donald E.Bray, Mark R.Pan, Guohua Mak, Tak W.	2014
	Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer Journal:Proceedings of the National Academy of Sciences of the United States of America	Mason, Jacqueline M.Wei, Xin Fletcher, Graham C.Kiarash, Reza Brokx, Richard Hodgson, Richard Beletskaya, Irina Bray, Mark R.Mak, Tak W.	2017
	Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms Journal:Leukemia	Murphy, Tracy Mason, Jacqueline M.Leber, Brian Bray, Mark R.Chan, Steven M.Gupta, Vikas Khalaf, Dina Maze, Dawn McNamara, Caroline J.Schimmer, Aaron D.Schuh, Andre C.Sibai, Hassan Trus, Michael Valiquette, Debbie Martin, Kylie Nguyen, Linh Li, Xuan Mak, Tak W.Minden, Mark D.Yee, Karen W.L.	1-Mar-2024
	Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial Journal:British Journal of Cancer	Veitch, Zachary W.Cescon, David W.Denny, Trisha Yonemoto, Lisa Maria Fletcher, Graham Brokx, Richard Sampson, Peter Li, Sze Wan Pugh, Trevor J.Bruce, Jeffrey Bray, Mark R.Slamon, Dennis J.Mak, Tak W.Wainberg, Zev A.Bedard, Philippe L.	2019
	Soluble Interleukin-13Rα2 Decoy Receptor Inhibits Hodgkin's Lymphoma Growth in Vitro and in Vivo Journal:Cancer Research	Trieu, Young Wen, Xiao Yan Skinnider, Brian F.Bray, Mark R.Li, Zhihua Claudio, Jaime O.Masih-Khan, Esther Zhu, Yuan Xiao Trudel, Suzanne McCart, J. Andrea Mak, Tak W.Stewart, A. Keith	2004
	Targeting Mitosis in Cancer: Emerging Strategies Journal:Molecular Cell	Dominguez-Brauer, Carmen Thu, Kelsie L.Mason, Jacqueline M.Blaser, Heiko Bray, Mark R.Mak, Tak W.	2015
	The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses Journal:Nature Immunology	Suh, Woong Kyung Gajewska, Beata U.Okada, Hitoshi Gronski, Matthew A.Bertram, Edward M.Dawicki, Wojciech Duncan, Gordon S.Bukczynski, Jacob Plyte, Suzanne Elia, Andrew Wakeham, Andrew Itie, Annick Chung, Stephen Da Costa, Joan Arya, Sudha Horan, Tom Campbell, Pauline Gaida, Kevin Ohashi, Pamela S.Watts, Tania H.Yoshinaga, Steven K.Bray, Mark R.Jordana, Manel Mak, Tak W.	2003
	The discovery of orally bioavailable tyrosine threonine kinase (TTK) inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as anticancer agents Journal:Journal of Medicinal Chemistry	Liu, Yong Lang, Yunhui Patel, Narendra Kumar Ng, Grace Laufer, Radoslaw Li, Sze Wan Edwards, Louise Forrest, Bryan Sampson, Peter B.Feher, Miklos Ban, Fuqiang Awrey, Donald E.Beletskaya, Irina Mao, Guodong Hodgson, Richard Plotnikova, Olga Qiu, Wei Chirgadze, Nickolay Y.Mason, Jacqueline M.Wei, Xin Lin, Dan Chi Chia Che, Yi Kiarash, Reza Madeira, Brian Fletcher, Graham C.Mak, Tak W.Bray, Mark R.Pauls, Henry W.	2015

Showing results 1 to 14 of 14